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a b s t r a c t
Understanding the pathomechanisms behind peripheral nerve damage and learning the
course of regeneration seem to be crucial for selecting the appropriatemethods of treatment.
Autografts are currently the gold standard procedure in nerve reconstruction. However, due
to the frequency of complications resulting from autografting and a desire to create a better
environment for the regeneration of the damaged nerve, artiﬁcial conduits have become an
approved alternative treatment method. The aim of this mini-review is to present the nerve
scaffolds that have been applied in clinical practice to date, and the potential directions of
developments in nerve conduit bioengineering.
Articles regarding construction and characterization of nerve conduits were used as the
theoretical background. All papers, available in PubMed database since 2000, presenting
results of application of artiﬁcial nerve conduits in clinical trials were included into this
mini-review.
Fourteen studies including ≤10 patients and 10 trials conducted on >10 patients were
analyzed as well as 24 papers focused on artiﬁcial nerve conduits per se. Taking into
consideration the experiences of the authors investigating nerve conduits in clinical trials,
it is essential to point out the emergence of bioresorbable scaffolds, which in the futuremay
the treatment of peripheral nerve injuries. Also worth mentioning
conduits are hybrid conduits, which combine several modiﬁcations ofamong the advanced
a synthetic material tsigniﬁcantly changeo provide the optimal regeneration of a damaged nerve.
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lenge for contemporary medicine and is the subject of research
aimed at developing new therapeutic strategies. Peripheral
nerve damage occurs in 13–20 of every 100,000 persons [186_TD$DIFF] 1], often
alongside other injuries. It also frequently concerns youngactive
persons, for whom even a partial loss of nerve function can
entail serious social and economic consequences.
Neurorrhaphy is a classic technique of direct nerve repair
without or minimal tension on the nerve repair site, but still
surgical treatments for peripheral nerve injury are less than
satisfactory. When there is a gap between the nerve ends with
excessive tension for direct epineural repair, reversed interpo-
sition autologous nerve grafts are required. The gold standard
of treatment for peripheral nerve gaps between 5 mmand 3 cm
in size is the nerve conduit or the autologous nerve graft,
interchangeably; however, this last treatment is always
associated with a variety of clinical complications, such as
donor site morbidity, limited availability, nerve site mismatch,
and the formation of neuromas [187_TD$DIFF] 2]. This procedure is also
limited by the number of potential autografts that may be
applied. Autograft treatment may also result in complications
in the form of sensory or pain disorders if a neuroma forms at
the graft collection site. Human autografts are preferred as the
literature is clear that autografting is superior to nerve conduits
for medium gaps (>3 cm), especially more proximal injuries,
and crucial nerves [188_TD$DIFF] 3]. Nerve grafts can be single, cable, trunk,
interfascicular, or vascularized [187_TD$DIFF] 2]. Autograft use is currently
limited to a critical nerve gap of approximately 5 cm in length
and beyond this distance requires the use of allograft. Allograft
however requires the use of extensive immune suppression up
to 18 months post implantation, and patients become
susceptible to opportunistic infections, occasionally resulting
in tumor formation [189_TD$DIFF] 4]. Alternatives to autologous nerve graft
are available and their use avoids sacriﬁcing donor site
sensation. Options includes empty silicon tubes for digital
nerve gaps of 5 mm or less, polyglycolic acid conduits and
polycaprolacton for gaps less than 3 mm and decellularized
muscle allograft for gaps to 5 cm [190_TD$DIFF] 2].
There are several factors that inﬂuence recovery following
a nerve injury and repair: time elapsed, patient age, mecha-
nism, proximity of the lesion to distal targets, and associated
soft tissue or vascular injuries [191_TD$DIFF] 5–7]. All these factors must be
carefully considered in order to optimize the operative
approach used in each unique patient.
Nerve conduits are currently being introduced in order to
minimize the risk of complications and at the same time to
stimulate nerve growth. A contemporary alternative to
autografts are conduits that are made from advanced
biodegradable materials [192_TD$DIFF] 8,9]. The aim of the presented paper
is to provide a concise review of implementation of various
types of approved nerve conduits in human therapy.
2. MethodsAn inspiration to write this paper was work associated
with the preparation of a research grant as well as ourearlier studies on nerve regeneration. PubMed database
was searched for articles focusing on different types of
nerve conduits, especially these approved for use in
human therapy. Nerve conduits paradigm as well as their
short history has been prepared. Every clinical trial on
application of nerve conduits in treatment of human nerve
injuries since 2000 has been tracked and presented in two
tables, according to the number of patients included (10
trials describing more than10 patients, and 14 trials dealing
with 10 patients or less).
3. Brief history of nerve conduitsThe use of a tube-like conduit was originally proposed for use
for nerve repair as early as in 1881 with the ﬁrst successful
application occurring in 1882, where a hollow bone tube was
used to bridge a 30 mm nerve gap in a dog [188_TD$DIFF] 3]. Contemporary,
the ﬁrst generation of artiﬁcial nerve conduits used in the
clinic were nonresorbable silicone tubes, whichwere plagued
by compression syndrome and often required secondary
surgeries for removal [193_TD$DIFF] 10]. Since then, there have been a
variety of different biomaterials approved for clinical use,
such as type I collagen, polyglycolic acid (PGA), poly-DL-
lactide-co-caprolactone (PLCL), and polyvinyl alcohol (PVA).
There currently are ﬁve FDA-approved nerve conduits, four of
which – Neurotube (PGA), Neurolac (PLCL), NeuraGen (type I
collagen), and NeuroMatrixNeuroﬂex (type I collagen) – are
bioresorbable (with degradation rates on the order of 3
months to 4 years), and one that is nonresorbable – SaluBridge
(PVA hydrogel) [194_TD$DIFF] 11]. Only results of clinical studies for
NeuraGen, Neurotube, and Neurolac have been published
in peer-reviewed journals.4. Directions of nerve conduit development
Modern biomedical engineering aims to create a conduit that
will ensure the appropriate repair, both structural and
functional, of a peripheral nerve. A perfect implant should
be non-toxic, minimally immunogenic, adjusted to the
severity of the injury, easy to manufacture and commonly
available, and should have an appropriate degradation time [195_TD$DIFF]
[9]. It should also create the proper micro-environment to
stimulate nerve regeneration.
The notion of an ideal material for conduit implantation
has evolved from silicone-based and other synthetic materi-
als, through biological conduits, to advanced synthetic
biodegradable materials. Fig. 1 presents the materials that
have been applied in clinical practice to date. Non-degradable
materials are no longer used due to the intense immunologi-
cal reactions they have caused. These reactions led to
swelling in the surrounding tissues, which in turn put
pressure on the nerve and hampered its regeneration.
Furthermore, the procedure required a follow-up surgery to
remove the conduit.
The most rapidly developing group of materials being used
to make nerve conduits, and the group with the greatest
potential, is bioresorbable materials. By modifying the
biological, structural, and chemical properties of a polymer,
[(Fig._1)TD$FIG]
Fig. 1 – Materials used in peripheral nerve conduit bioengineering.
[(Fig._2)TD$FIG]
Fig. 2 – Directions in the development of peripheral nerve
conduit biotechnology.
Table 1 –Major growth factors for nerve
tissue [156_TD$DIFF] 33].
NGF – nerve growth factor
GGF – glial growth factor
FGF – ﬁbroblast growth factor
GDNF – glial cell-derived neurotrophic factor
BDNF – brain-derived neurotrophic factor
NT-3 – neurotrophin-3
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regeneration, which is a priority in the production of an
appropriate material. Fig. 2 presents the key directions in the
development of conduit biotechnology.
4.1. Growth factors
One of the methods used for creating an appropriate micro-
environment for axon growth involves enriching the conduits
with growth factors that are relevant for the nerve tissue [196_TD$DIFF] 12–
14], which promote chemotactic nerve regeneration. Themostimportant growth factors can be found in Table 1. A
combination of several growth factors (e.g., NGF or GDNF) [197_TD$DIFF] 6]
and enriching the material with the aforementioned cells that
are able to produce cytokines seems to be the most beneﬁcial
approach [198_TD$DIFF] 15].
Application of neurotrophic substances separately does not
result in signiﬁcant improvement of the nerve repair rate.
Moreover, it is extremely difﬁcult to ﬁnd an appropriate
concentrations of these factors. In spontaneous nerve regen-
eration, these factors act as a ‘‘changing-in-time cocktail’’ (i.e.
the mixture of various substances whose concentration and
activity changes in time). Therefore, it is of special importance
to apply different neuroactive substances in the proper
constellation [199_TD$DIFF] 16].
The distal stump undergoes Wallerian degeneration,
producing a favorable environment for ﬁbers growing from
proximal stump. Therefore, some attempts were made to
plant cultured Schwann cells that serve as a natural source of
such neuroactive substances into the vicinity of regenerating
nerves with. The authors of this work have high experience
Table 2 – Characteristic amino acid sequences in ECM [157_TD$DIFF] 11].
Name of the sequence Amino acids
RGD Arg–Gly–Asp
IKVAV Ile–Lys–Val–Ala–Val
YIGSR Tyr–Ile–Gly–Ser–Arg
RNIAEIIKDI Arg–Asn–Ile–Ala–Glu–Ile–Ile–Lys–
Asp–Ile
HAV His–Ala–Val
[(Fig._3)TD$FIG]
Fig. 3 – Procedure used in treating peripheral nerve injuries.
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obtained from degenerating peripheral nerves and Schwann
cells population to support peripheral nerve regeneration [200_TD$DIFF] 16].
This approach is similar to the Umea group who additionally
enrich the ﬁbrin conduit with the human mesenchymal stem
cells using immunosuppressive therapy to enhance survival
graft cells after their transplantation [201_TD$DIFF] 17].
4.2. Appropriate material
One of the most important considerations in developing a
conduit is the choice of an appropriate structural material. An
ideal structural material for manufacturing conduits should [202_TD$DIFF]
[18–20]: Be biocompatible with the surrounding tissues – such
biocompatibility can be achieved by using a porous
structure, which will enable a free exchange of nutrients
and ensure the appropriate vasculature and concentration
of neural growth factors (studies conducted so far indicate
that the use of nanoporesmeasuring about 100 nm in size is
beneﬁcial) [203_TD$DIFF] 18]; Provide enough room for the growing axon;
 Have an adequate bioresorption time;
 Have low immunogenicity;
 Have an appropriate structure to enable the supply of
regenerative substances (a microsphere structure); Adhere to the cells in an appropriate manner – this depends
especially on the hydrophobicity of the material.
4.3. Contact with the extracellular matrix
The extracellular matrix is an important component that
affects nerve regeneration. It regulates the cell migration and
myelination, and stimulates the diffusive release of growth
factors from the Schwann cells. The numerous proteins that
are responsible for intercellular contact in the ECM contain
similar amino acid sequences (Table 2), the most common of
which is the RGD sequence, i.e., Arg-Gly-Asp. These sequences
allow particular receptors to recognize and exchange signals
with each other, which stimulates the growth,maturation and
differentiation of the cells. As a result, coating the conduits
with unique amino acid sequences will beneﬁt the adherence
and differentiation of Schwann cells, create an advantageous
environment that is rich in growth factors (especially NGF and
BDNF), and will minimize oxidative stress. Furthermore, the
conduit will constitute a scaffold for the regenerating nerve,
which is especially important in the initial stages of repair [204_TD$DIFF] 21].4.4. Nanoparticles and nanoﬁbers
Another modiﬁcation to standard polymers involves adding a
structure of nanoparticles or nanoﬁbers [205_TD$DIFF] 22]. These form a
multiphase surface that allows for a more efﬁcient interaction
between the conduit and the ECM, and a better adhesion.
Moreover, the interaction between the nanostructure and the
polymer changes the thermal, optical, chemical, and catalytic
properties of the conduit in a manner which can potentially
beneﬁt nerve regeneration [206_TD$DIFF] 23].
The use of a proper material and each of the aforemen-
tioned modiﬁcations will improve the effectiveness of nerve
implants in promoting nerve growth, as has been conﬁrmed by
numerous studies conducted on animal models. The most
successful method seems to involve combining several
modiﬁcations in order to create a hybrid implant [207_TD$DIFF] 24] that
enables optimal nerve regeneration in the shortest time
possible.5. Practical applications and clinical trials
conducted to dateThe preferred procedure in cases of minor peripheral nerve
damage (i.e. in cases where continuity can be restoredwithout
tensing the damaged nerve) is the direct suturing of the
epineurium with funicular sutures. For more severe damage,
autografts are commonly used. Fig. 3 presents the currently
most popular procedure.
In 2008, the FDA (Food and Drug Administration) and CE
(Conformit Europe) approved the use of nerve conduits made
from, among other materials, collagen, PGA and PCL. Accord-
[(Fig._4)TD$FIG]
Fig. 4 – The graphical presentation nerve conduits available on the market and their commercial names. The color specifying
the type of material of which are built [155_TD$DIFF] 17].
Table 3 – MRC scale for the assessment of sensory and
motor function reestablishment.
Degree MRC scale S-2-PD
S0 Function not reestablished –
S1 Deep pain reestablished –
S1+ Surface pain reestablished –
S2 S1+ and partial response to touch –
S2+ S2 and over-response –
S3 Surface pain and response to
touch reestablished
>15 mm
S3+ S3 and good localization of touch,
imperfect 2-PD
7–15 mm
S4 Function completely
reestablished
2–6 mm
M0 No contraction
M1 Barely visible contraction, no
movement
M2 Active movement, no gravity
M3 Active movement, against gravity
M4 M3 and movement against
resistance
M5 Normal muscle strength
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conduits was limited to lesionsmeasuring less than 3 cm long
in the peripheral and cranial nerves [208_TD$DIFF] 25,26]. Fig. 4 lists the
approved conduits available on themarket together with their
commercial names. Despite the approval and availability of
conduits made from various materials, studies on the subject
remain scarce. Furthermore, the existing studies usually
involve an insufﬁcient number of cases, lack a control sample,
and use no reference method, all of which decreases theirreliability. Table 3 lists the clinical trials that have been
conducted since 2000 in which the number of patients in the
experimental group was higher than 10. All of their authors
evaluated the applied methods in a similar manner, i.e., they
used the Medical Research Scale (MRC) to analyze the
returning sensory and/or motor functions (through a static
two-point discrimination, s2PD). Table 4 shows the individual
values and a detailed description of the scale. The results are
divided into three subgroups: Very good results (when the function at the level of S4/S3+ or
M5/M4 was reestablished in ≥70% of the patients); Satisfactory results (when the function at the level of S4/S3+
or M5/M4 was reestablished in 50–70% of the patients); and Unsatisfactory results (when the function at the level of S4/
S3+ or M5/M4 was reestablished at the level of S4/S3+ or M5/
M4 in ≤50% of the patients).
Table 4 indicates that only 10 clinical trials involving
more than 10 patients have been conducted so far. All of
these trials have concerned nerve damage in the upper
limbs, mainly in the hands and ﬁngers. In accordance with
the applied procedure, the lesion measured no longer than
3 cm. The trials focused on the restoration of the patient's
sensory functions. Only two studies (by Wagensteen et al. [209_TD$DIFF]
[27] and Boeckstyns et al. [210_TD$DIFF] 28]) analyzed themotor functions.
Of the studies, Wagensteen's is the least reliable due to its
retrospective character and the fact that the injury was
measured in only 26 cases, and also no follow-up study was
conducted for as many as 40 of the 126 reconstructed nerves
(all of which makes the obtained ‘‘unsatisfactory results’’
unreliable) [211_TD$DIFF] 27].
Table 4 – Studies on the use of peripheral nerve conduits conducted since 2000 with experimental groups of >10 patients.
N – number of patients, F-UP – follow-up, MF – motor function, SF – sensory function, PGA – polyglycolic acid, PLCL –
polylactide-caprolactone.
Author Year Type of study Lesion, length Conduit Conduits
(N)
control
(N)
F-UP
(months)
Conclusions
Weber et al. [158_TD$DIFF] 29] 2000 Prospective,
randomized,
multicenter
Nerves of the hand PGA vs.
Standard
46 56 12 Conduits are more
effective than the
standard method, very
good results (SF)
Taras et al. [159_TD$DIFF] 36] 2005 Prospective Peripheral nerves Collagen 73 N/A N/A N/A
Bertleff et al. [160_TD$DIFF] 30] 2005 Prospective,
randomized,
multicenter
Nerves of the hand,
<20 mm
PLCL vs.
Standard
21 13 12 Both groups are
comparable
Wangensteen,
Kalliainen [161_TD$DIFF] 27]
2009 Retrospective 82 nerves of the hand,
34 other nerves of the
upper limb, 6 nerves of
other body parts,
average 12.8 mm
Collagen 126 N/A 8 Unsatisfactory results:
functions improved in
45% of patients (SF and
MF), many limitations
in the trial
Lohmeyer et al [162_TD$DIFF].[37] 2009 Prospective Nerves of the hand,
average 12.5 mm
Collagen 12 N/A 12 Very good results (SF)
Rinker, Liau. [163_TD$DIFF] 38] 2011 Prospective,
randomized
Nerves of the ﬁngers,
4–25 mm
PGA vs. Vein
autograft
36 32 12 Very good results, both
methods are effective,
no statistical
differences (SF)
Taras et al. [164_TD$DIFF] 39] 2011 Prospective Nerves of the ﬁngers,
average 12 mm
Collagen 22 N/A 20 Very good results (SF)
for lesions <2 cm long
Boeckstyns et al [165_TD$DIFF].[40] 2013 Prospective,
randomized
Ulnar or median
nerve, <6 mm
Collagen vs.
Nerve
suturing
16 16 24 No differences after 24
months, both methods
are very good (SF and
MF)
Schmauss et al. [166_TD$DIFF] 41] 2014 Prospective Nerves of the ﬁngers,
<26 mm
Collagen 20 N/A 30–93 Very good results (FS),
better results obtained
for lesions < 10 mm
long
Lohmeyer et al. [167_TD$DIFF] 42] 2014 Prospective Nerves of the ﬁngers,
<26 mm
Collagen 40 N/A 12 Satisfactory results (SF)
[(Fig._5)TD$FIG]
Fig. 5 – Graphic presentation the number of all patients with
nerve implants according to the type of conduit used.
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randomization with respect to the ‘‘gold standard’’ treatment.
Each of these trials used a different material for the
randomization (Weber used PGA; Bertleff used PLCL; andBoeckstyns used collagen) [212_TD$DIFF] 28–30]. Weber showed that the
conduits were more effective than the standard procedure.
However, Bertleff and Boeckstyns obtained similar, very good
resultswhen the conduitswere compared to the control group [213_TD$DIFF]
[29,39]. Most of the patients underwent a follow-up assess-
ment 12 months after the surgery; however, this may have
been too early in light of Schmauss's study, who showed that
nerve regeneration is still incomplete after this period [214_TD$DIFF] 28].
Table 5 shows the clinical trials conducted on smaller
groups of patients (≤10). In addition to injuries of the upper
limbs, injuries involving lesions of the cranial nerves or the
nerves in the brachial plexus that accompanied injuries to
other body parts were included in the trials. Most of the
patients were screened for the restitution of both sensory and
motor functions. The conduitswere used for lesions shorter, as
well as longer, than 3 cm [215_TD$DIFF] 31–33,35]. Very good results were
obtained.
The two tables indicate that the most commonly used
material in the studies was a collagen conduit, or other
conduits with a simple structure, such as polyglycolic acid.
Fig. 5 shows the types of the conduits and the respective
numbers of patients. Only a very small group of patients (14
persons) have had a modern hybrid conduit implanted.
Furthermore, Yin et al. were the only researchers who used
an advanced hybrid type of implant [216_TD$DIFF] 34]. These hybrid
Table 5 – Studies on the use of peripheral nerve conduits conducted since 2000 with experimental groups of ≤10 patients. N
– number of patients, MF – motor function, SF – sensory function, PGA – polyglycolic acid, PDLLA – poly-DL-lactide, PHB –
polyhydroxybutyrate, PGRD – RGD sequence, b-TCP – beta-tricalcium phosphate.
Author Year Lesion, length Type of conduit Conduits (N) Results
Kim, Dellon [168_TD$DIFF] 43] 2001 Reconstruction following the
excision of a neuroma of the
medial plantar nerve
PGA 1 Reduced pain, good regeneration
Ducic et al. [169_TD$DIFF] 44] 2005 Accessory nerve PGA vs.
Autograft
1 MF improved in the patient with
the conduit
Navissano et al. [170_TD$DIFF] 45] 2005 Facial nerve, <30 mm PGA 7 Very good reestablishment of MF
Ashley et al. [171_TD$DIFF] 31] 2006 Brachial plexus in children Collagen 5 Very good results
Fan et al. [172_TD$DIFF] 46] 2008 Median nerve, 35 mm Chitosan-PGA 1 Satisfactory reestablishment of
MF and SF
Farole, Jamal [173_TD$DIFF] 47] 2008 Lingual nerve, inferior
alveolar nerve, 15 mm
Collagen 9 Very good/satisfactory results
Bushnell et al. [174_TD$DIFF] 48] 2008 Nerves of the ﬁngers,
<20 mm
Collagen 9 Very good results, SF
Rosson et al. [175_TD$DIFF] 49] 2009 Peripheral nerves, <40 mm PGA 6 Very good results
Aberq et al. [176_TD$DIFF] 33] 2009 Nerves of the forearm PHB vs.
suturing
6 Satisfactory reestablishment of
SF, unsatisfactory
reestablishment of MF
Tsujimoto et al. [177_TD$DIFF] 50] 2011 Autonomic/somatic nerves in
the pelvis, 25–90 mm
PGA-collagen Autonomic nerves (7),
Somatic nerves (3)
Very good improvement for both
autonomic and somatic nerves
Jardin et al. [178_TD$DIFF] 51] 2011 Nerves of the forearm,
average 22 mm
Collagen 4 Very good re-establishment of MF
and SF
Gu J et al. [179_TD$DIFF] 52] 2012 Median nerve, 30 mm Chitosan-PGA 1 Partial reestablishment of
autonomic function, SF and MF
Semere et al. [180_TD$DIFF] 53] 2014 Facial nerve, 10 mm Collagen 1 Very good improvement after 6
months
Yin et al. [181_TD$DIFF] 54] 2015 Radial/medial nerve, <25 mm PRGD/PDLLA/b-
TCP
2 Very good results, about 80% of
MF and SF re-established
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neutralizes the products of PDLLA biodegradation and accel-
erates their removal, as well as improving the adherence of
cells to the conduit and the RGD structure characteristic for the
ECM. These unique properties of the material may have
contributed to the very good clinical results obtained in both of
the cases described in the study.
6. ConclusionsDespite a small number of trials, insufﬁcient reliability, and a
modest size of the samples, that appeared the biggest
limitations for this review, the obtained results are nonethe-
less encouraging, and prove that therapy performed using
nerve conduits as an alternative to standard procedures is
both safe and viable.
Further clinical trials with a high level of reliability need to
be conducted. Furthermore, more technologically advanced
conduits should be used, to keep up with the progress in
bioengineering. Such conduits should include hybrid
implants, especially full neural scaffolds with a polymer core
that imitates the both the outer layer of the nerve and the
endoneurium, rather than conduits that imitate the outer
layer alone. Amilestone, especially in repairing the nerve gaps
of a big size, might be the enrichment of the internal
environment of the conduit by adding mixture of growth
factors and adhesion proteins. But one must remember thatthe use of growth factors may cause many undesired side
effects because to date knowledge of their physiological
concentrations is still unsatisfactory.
Conﬂict of interestNone declared[217_TD$DIFF][153_TD$DIFF].
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